Quick Answer
SAB Biotherapeutics, Inc. reported Operating Income of -$48.95 million for fiscal year 2025.
SAB Biotherapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$48.95M | -14.1% |
| 2024 | -$42.91M | -12.7% |
| 2023 | -$38.08M | -31.7% |
| 2022 | -$28.92M | -115.9% |
| 2021 | -$13.39M | -165.2% |
| 2020 | $20.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$12.68M | -12.1% | -30.3% |
| June 30, 2025 | -$9.73M | +4.6% | +9.7% |
| March 31, 2025 | -$10.77M | +5.4% | +4.8% |
| September 30, 2024 | -$11.31M | -112.5% | -10.9% |
| June 30, 2024 | -$10.20M | -57.5% | +10.4% |
| March 31, 2024 | -$11.39M | -53.9% | -114.0% |
| September 30, 2023 | -$5.32M | +31.8% | +17.8% |
| June 30, 2023 | -$6.48M | +1.0% | +12.5% |
- SAB Biotherapeutics, Inc. showed a decrease of -14.1% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s operating income has declined by 338.1% (from $20.56 million to -$48.95 million).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: